FDA clears denifanstat Phase 3 trial as Sagimet targets once-daily oral acne treatment
FDA clears Sagimet’s 800-patient denifanstat Phase 3 acne trial after positive China data. Read why the U.S. study could reshape its outlook.
Pharma & Biotech